Cargando…

Device-assisted intravesical therapy for non-muscle invasive bladder cancer

Non-muscle invasive bladder cancer (NMIBC) is a challenging disease, with a high risk of recurrence and even progression to muscle invasive disease. The present standard treatment is suboptimal, and consists of a complete transurethral resection of the visible bladder tumour(s), followed by prophyla...

Descripción completa

Detalles Bibliográficos
Autor principal:	Hendricksen, Kees
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414348/ https://www.ncbi.nlm.nih.gov/pubmed/30976573 http://dx.doi.org/10.21037/tau.2018.09.09

Ejemplares similares

Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients
por: de Jong, Joep J., et al.
Publicado: (2018)

Intravesical chemotherapy in non-muscle-invasive bladder cancer
por: Porten, Sima P., et al.
Publicado: (2015)

The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer
por: Douglass, Laura, et al.
Publicado: (2016)

Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer
por: Hendricksen, Kees, et al.
Publicado: (2009)

Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo(®) working party
por: Alfred Witjes, J., et al.
Publicado: (2009)

Emerging intravesical therapies for management of nonmuscle invasive bladder cancer
por: Tomaszewski, Jeffrey J, et al.
Publicado: (2010)

Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy
por: Serretta, Vincenzo, et al.
Publicado: (2015)

Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review
por: Han, Mi Ah, et al.
Publicado: (2021)

Intravesical immunotherapy in nonmuscle invasive bladder cancer
por: Jokisch, Jan-Friedrich, et al.
Publicado: (2015)

Non-Invasive Imaging Modalities in Intravesical Murine Models of Bladder Cancer
por: Relouw, Sydney, et al.
Publicado: (2023)

Impact of Effective Intravesical Therapies on Quality of Life in Patients with Non-Muscle Invasive Bladder Cancer: A Systematic Review
por: Yuen, John W., et al.
Publicado: (2022)

High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
por: Veeratterapillay, Rajan, et al.
Publicado: (2016)

Renal Granulomatosis Post Intravesical Bacillus Calmette–Guerin Therapy for Non-muscle-invasive Bladder Cancer
por: Tran-Harding, Karen, et al.
Publicado: (2018)

Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence
por: Zhang, Jianglei, et al.
Publicado: (2021)

Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer
por: Steinberg, Ryan L., et al.
Publicado: (2015)

Novel intravesical therapeutics in the treatment of non-muscle invasive bladder cancer: Horizon scanning
por: Ward, Kelly, et al.
Publicado: (2022)

Intravesical Gemcitabine versus Intravesical Bacillus Calmette–Guérin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity
por: Prasanna, Thiru, et al.
Publicado: (2017)

Sex Remains Negative Prognostic Factor in Contemporary Cohort of High-Risk Non-Muscle-Invasive Bladder Cancer
por: Bilski, Konrad, et al.
Publicado: (2022)

Efficacy and toxicity of intravesical Bacillus Calmette-Guérin therapy in elderly patients with non-muscle-invasive bladder cancer
por: Matsuoka, Yuki, et al.
Publicado: (2021)

Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical Therapy
por: Miyata, Yasuyoshi, et al.
Publicado: (2015)

Impact of intravesical Bacillus Calmette-Guérin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer
por: James, Christopher, et al.
Publicado: (2023)

Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer
por: Milbar, Niv, et al.
Publicado: (2017)

Redefining the role of immediate intravesical instillation of mitomycin C in non-muscle invasive bladder cancer
por: Batura, Deepak
Publicado: (2018)

Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer
por: Magalhães, Joana C, et al.
Publicado: (2023)

Intravesical Therapy for Non-Muscle-Invasive Bladder Cancer: What Is the Real Impact of Squamous Cell Carcinoma Variant on Oncological Outcomes?
por: Mantica, Guglielmo, et al.
Publicado: (2022)

TERT C228T mutation in non‐malignant bladder urothelium is associated with intravesical recurrence for patients with non‐muscle invasive bladder cancer
por: Hayashi, Yujiro, et al.
Publicado: (2020)

Oncolytic immunotherapy for the treatment of non-muscle invasive bladder cancer using intravesical coxsackievirus A21
por: Annels, Nicola E, et al.
Publicado: (2015)

Editorial on the value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer
por: Oosterlinck, Willem, et al.
Publicado: (2018)

Emerging concepts and spectrum of renal injury following Intravesical BCG for non-muscle invasive bladder cancer
por: Mohammed, Azharuddin, et al.
Publicado: (2017)

The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer
por: Chen, Jian-Xin, et al.
Publicado: (2023)

Is Intravesical Bacillus Calmette-Guérin Therapy Superior to Chemotherapy for Intermediate-risk Non-muscle-invasive Bladder Cancer?: An Ongoing Debate
por: Han, Kyung-Sik, et al.
Publicado: (2015)

HER-2 overexpression is a negative predictive factor for recurrence in patients with non-muscle-invasive bladder cancer on intravesical therapy
por: Moustakas, Georgios, et al.
Publicado: (2020)

Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer
por: Pak, Sahyun, et al.
Publicado: (2021)

The impact of different adjuvant intravesical therapy methods on tumor biology in patients with high-risk non-muscle-invasive bladder cancer
por: Kostyev, Fedir, et al.
Publicado: (2021)

Long-Term Experience with Radiofrequency-Induced Hyperthermia Combined with Intravesical Chemotherapy for Non-Muscle Invasive Bladder Cancer
por: Brummelhuis, Iris S. G., et al.
Publicado: (2021)

Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after Bacillus Calmette-Guérin failure
por: Shantharam, Govind, et al.
Publicado: (2021)

Hyperthermic intravesical chemotherapy with mitomycin‐C for the treatment of high‐risk non‐muscle‐invasive bladder cancer patients
por: Conroy, Samantha, et al.
Publicado: (2022)

PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non‐muscle‐invasive bladder cancer
por: Woodcock, Victoria K., et al.
Publicado: (2023)

Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis
por: Zhuo, Chuanjun, et al.
Publicado: (2016)

Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections
por: van Puffelen, Jelmer H, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bal0bsql2n5ddtplautfmvlsna